Supplementary Table 1. The levels of thrombogenic biomarkers in patients of CHA$_2$DS$_2$-VASc score ≥2

Variables	CLPD group (n=12)	CILO group (n=8)	PUFA group (n=6)	p
vWF:Ag (IU/dL)				
Aspirin monotherapy	164.3±34.3	153.0±34.8	137.6±15.2	0.396
Combination therapy	151.9±37.0	144.8±33.4	129.7±26.0	0.487
LS mean difference	12.4	8.2	7.9	
95% CI of difference	-9.7 to 34.5	-10.2 to 26.5	-17.2 to 32.9	
p value	0.272	0.401	0.345	
Fibrinogen (mg/dL)				
Aspirin monotherapy	319.3±56.8	316.3±103.6	315.5±55.2	0.217
Combination therapy	291.1±62.3	313.4±66.5	291.5±47.8	0.334
LS mean difference	28.2	2.9	24.0	
95% CI of difference	-2.5 to 58.8	-32.4 to 38.2	-8.0 to 56.0	
p value	0.071	1.000	0.116	
D-dimer (ng/mL)				
Aspirin monotherapy	938.3±1404.7	486.3±312.6	305.0±151.2	0.787
Combination therapy	945.0±1530.5	482.5±261.5	381.7±142.3	0.537
LS mean difference	-6.7	3.8	-76.7	
95% CI of difference	-218.2 to 204.8	-165.9 to 173.4	-205.8 to 52.5	
p value	0.530	0.889	0.115	
hs-CRP (μg/dL)				
Aspirin monotherapy	119.2±138.6	82.5±47.7	173.3±145.7	0.814
Combination therapy	121.7±132.2	78.8±66.6	110.0±61.6	0.585
LS mean difference	33.5	3.8	63.3	
95% CI of difference	-2.5 to 186.8	-58.0 to 65.5	-59.4 to 186.0	
p value	0.767	0.865	0.292	

Values are presented as mean±standard deviation or number. CLPD: clopidogrel, CILO: cilostazol, PUFA: omega-3 polyunsaturated fatty acid, vWF:Ag: von Willebrand factor antigen, LS: least squares, CI: confidence interval, hs-CRP: high sensitivity C-reactive protein